QUANTICA
10.11.2022 11:46:41 CET | Business Wire | Press release
Last November at the international additive manufacturing exhibition Formnext, Quantica announced its T1 Pro, an R&D system that showcased the company’s multi-material, ultra-high viscosity jetting capabilities, known as NovoJet™. A year later, Quantica is back at the Frankfurt-based expo, this time introducing a new Desktop system– the NovoJet™ C-7.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221110005047/en/
The Berlin-based 3D printing start-up is pushing the boundaries of multi-material and high-performance material jetting, through the introduction of the NovoJet™ C-7. A printer suitable for research, feasibility studies, and small scale production of custom applications. It will be made available to research institutes and industry partners, looking to develop high-performance, multi-material 3D printing and other additive manufacturing applications.
NovoJet™ C-7 is an open printing platform, ideal for 2D and 3D application development using Quantica’s ultra-high viscosity jetting technology. It has been created for research institutes, R&D labs, and organizations looking to develop new additive manufacturing materials and workflows. Beyond feasibility testing and application development, the printer can also be used for customized and low-volume production, enabling a truly seamless transition from lab to production.
Key features of the NovoJet™ C-7 include:
- Material Experimentation: The system uses printheads capable of handling a wide range of fluids with viscosities exceeding 380mPa•s at jetting temperature, equating to approximately 4000mPa•s at ambient temperature. Along with experimentation with liquids with high particle loading.
- New Material Combinations: The system has the ability to control up to 7 material channels giving users access to new material combinations with better mechanical properties, color fidelity, and aesthetics.
- System Customization: The system offers customizable integrations for research and development needs.
The power of Quantica’s NovoJet™ printhead technology is its ability to print materials that are 15 times more viscous than legacy inkjet printheads. This opens up new possibilities for delivering high value end-part products with properties such as high toughness, temperature resistance, conductivity, biocompatibility, and flexibility manufactured in a single process.
Multiple industry partners, mainly within the dental, medical and electronics space, have started collaborations with Quantica to develop targeted solutions based on the novel capabilities.
“This new system unlocks enormous possibilities for the material deposition industries, giving material developers the ability to move past the limitations of low performance fluids and start developing new formulations with better properties of interest. In the end, we empower organizations to build products in new and exciting ways,” said Ramon Borrell, CTO of Quantica. “Quantica is already exploring several applications in the dental, healthcare, consumer goods, and electronics industries. We are excited to support these, and the many other, industries in breaking down current inkjet barriers and limitations.”
For more information about the NovoJet™ C-7, please visit https://quantica3d.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005047/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom